v**********m
发帖数: 5516 | 1 XOMA 052 Shows Potent In Vitro Inhibition of Interleukin-6 Production in
Human Myeloma Cells
BERKELEY, Calif., Apr 19, 2010 (GlobeNewswire via COMTEX) -- XOMA Ltd. /
quotes/comstock/15*!xoma/quotes/nls/xoma (XOMA 0.80, +0.08, +11.30%) , a
leader in the discovery and development of therapeutic antibodies, announced
that independent researchers today presented results showing that XOMA's
antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective
in reducing production of a protein that supports the proliferation of
cancerous human myeloma cells in vitro. These results are consistent with a
47 patient clinical trial in early-stage myeloma patients which demonstrated
that IL-1 blockade with IL-1 receptor antagonist Kineret(R) (anakinra) in
combination with standard therapy improved progression-free survival. The
new data were presented at the 101st Annual Meeting of the American
Association of Cancer Research (AACR) (Abstract # 2449).
IL-1 beta stimulates the production of interleukin-6 (IL-6), a protein that
is a potent growth factor for myeloma cells. XOMA 052 is a high affinity
antibody that inhibits IL-1 beta activity. The results presented at the AACR
meeting indicated that XOMA 052 reduced IL-1 beta-induced IL-6 production
in the myeloma patient samples by more than 85%, which was superior to the
effects of the anti-inflammatory drug dexamethasone commonly used to treat
myeloma. The reduction with XOMA 052 was greater than 90% in samples from
the patients with the highest levels of IL-6 production. The researchers
concluded that treatment with an antibody such as XOMA 052 in combination
with standard therapy may be useful in myeloma patients who demonstrate
elevated IL-6 levels.
"These results provide another example of the broad clinical potential for
IL-1 beta targeting with XOMA 052" said Steven B. Engle, XOMA's Chairman and
Chief Executive Officer. "While the focus of our current XOMA 052 clinical
development program is on diabetes and cardiovascular disease, we are
pleased that results such as those presented today provide additional
avenues for exploration through collaborations at leading research and
clinical institutions." | h*****8
发帖数: 4754 | 2 NND,前几天加的居然入水这么久。
announced
a
demonstrated
【在 v**********m 的大作中提到】
: XOMA 052 Shows Potent In Vitro Inhibition of Interleukin-6 Production in
: Human Myeloma Cells
: BERKELEY, Calif., Apr 19, 2010 (GlobeNewswire via COMTEX) -- XOMA Ltd. /
: quotes/comstock/15*!xoma/quotes/nls/xoma (XOMA 0.80, +0.08, +11.30%) , a
: leader in the discovery and development of therapeutic antibodies, announced
: that independent researchers today presented results showing that XOMA's
: antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective
: in reducing production of a protein that supports the proliferation of
: cancerous human myeloma cells in vitro. These results are consistent with a
: 47 patient clinical trial in early-stage myeloma patients which demonstrated
| L********3
发帖数: 2272 | |
|
